Kingbact Tablet DT is a combination pharmaceutical formulation containing Cefixime 200 mg and Lactobacillus 2.5 Billion Spores, designed for the effective management of bacterial infections while supporting gastrointestinal flora. Cefixime, a third-generation cephalosporin antibiotic, exhibits broad-spectrum bactericidal activity by inhibiting bacterial cell wall synthesis, making it effective against various Gram-positive and Gram-negative pathogens. The inclusion of Lactobacillus, a probiotic strain, aids in maintaining and restoring the natural balance of intestinal microflora, which may be disrupted during antibiotic therapy, thereby reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances. Kingbact Tablet DT is formulated as a dispersible tablet to facilitate ease of administration, especially in patients with swallowing difficulties. It is indicated for the treatment of respiratory tract infections, urinary tract infections, otitis media, and uncomplicated gonorrhea, among other susceptible bacterial infections. The combination therapy ensures both eradication of pathogenic bacteria and preservation of beneficial gut bacteria. Dosage and duration should be determined by a healthcare professional based on the severity and type of infection. Caution is advised in patients with a history of hypersensitivity to cephalosporins or probiotics. Kingbact Tablet DT should be used under medical supervision to optimize therapeutic outcomes and minimize adverse effects.